Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On February 3, 2022, the Company announced that its Board of Directors (the
"Board"), as part of its ongoing leadership succession planning, has appointed
James E. Davis, currently Executive Vice President, General Diagnostics, to be
its next Chief Executive Officer and President, effective November 1, 2022. In
addition, Mr. Davis was appointed Chief Executive Officer - Elect, effective
February 3, 2022.
On November 1, 2022, Mr. Davis will succeed Stephen H. Rusckowski, who will have
served as Chief Executive Officer and President for more than a decade. Mr.
Rusckowski, 64, currently Chairman, Chief Executive Officer and President, will
continue to serve on the Board as Executive Chairman through March 2023.
Mark J. Guinan, the Company's Executive Vice President and Chief Financial
Officer, will retire in 2022. The Company has begun a search to identify Mr.
Guinan's successor. Mr. Guinan will participate in the selection process and is
expected to remain in his role through the transition.
Mr. Davis is not party to any transaction required to be disclosed pursuant to
Item 404(a) of Regulation S-K. There are no family relationships between Mr.
Davis and any director or executive officer of the Company. There are no
arrangements or understandings between Mr. Davis and any person, including any
officer or director of the Company, pursuant to which Mr. Davis was selected to
serve as Chief Executive Officer.
A copy of the press release announcing these management changes is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1 Press Release dated February 3, 2022, announcing management changes .
104 The cover page from this current report on Form 8-K, formatted in Inline XBRL.
© Edgar Online, source Glimpses